TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26140494

Group type: EXPERIMENTAL
Intervention: Double procedures (using both STA branches)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Single procedures (using only 1 STA branch)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Patients with diabetes mellitus (DM)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Patients without diabetes mellitus (DM)
Number of subjects: 71
Study: 23756315

Group type: EXPERIMENTAL
Intervention: 1.23% fluoride foam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo foam
Number of subjects: 100
Study: 21175276

Group type: EXPERIMENTAL
Intervention: Computer-guided GIN therapy (GINCS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Manually controlled GIN therapy
Number of subjects: 36
Study: 19724043

Group type: EXPERIMENTAL
Intervention: Mass distribution of oral azithromycin (1 g for adults, 20 mg/kg for children) administered to communities with over 80% coverage for children aged 1 to 9 years.
Number of subjects: 66404

Group type: COMPARATOR
Intervention: Control group (no treatment for 1 year) with 18,498 participants.
Number of subjects: 66404

Group type: EXPERIMENTAL
Intervention: Treated communities (mass azithromycin distribution).
Number of subjects: 66404
Study: 15812373

Group type: EXPERIMENTAL
Intervention: 360 degrees data acquisition
Number of subjects: 43

Group type: COMPARATOR
Intervention: 180 degrees data acquisition
Number of subjects: 43

Group type: COMPARATOR
Intervention: Echocardiography
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both methods (180 degrees and 360 degrees)
Number of subjects: 43
Study: 12714876

Group type: EXPERIMENTAL
Intervention: 10 mg/day lercanidipine (n = 48)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 5 mg/day amlodipine (n = 44)
Number of subjects: 92
Study: 10380951

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 6
Study: 8891644

Group type: EXPERIMENTAL
Intervention: Fast regular saccades
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Express saccades
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipatory saccades
Number of subjects: 0
Study: 1909286

Group type: EXPERIMENTAL
Intervention: Persumbran (25 mg dipyridamole + 10 mg oxazepam)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study: 6841827

Group type: EXPERIMENTAL
Intervention: Immediate food hypersensitivity (food challenges)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (placebo challenges)
Number of subjects: 26
Study: 31152042

Group type: EXPERIMENTAL
Intervention: Intervention development process
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Consideration of intervention's feasibility and long-term sustainability
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Drivers of intervention development
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Evaluation prioritization
Number of subjects: 21
Study: 28660314

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal gum
Number of subjects: 40
Study: 24916684

Group type: EXPERIMENTAL
Intervention: TeenDrivingPlan (TDP)
Number of subjects: 107
Study: 24836352

Group type: EXPERIMENTAL
Intervention: Enalapril/lercanidipine combination (20/10 mg)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Lercanidipine (10 mg)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 359
Study: 20854932

Group type: EXPERIMENTAL
Intervention: Triple-ARV prophylaxis continued during breastfeeding
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Short-course ARV prophylaxis stopped at delivery
Number of subjects: 1140
Study: 19472862

Group type: EXPERIMENTAL
Intervention: Distant healing performed by a professional Japanese healer for a 2-month period after a 20-minute group meditation session.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Distant healing performed by a professional Japanese healer.
Number of subjects: 17
Study: 17589951

Group type: EXPERIMENTAL
Intervention: Two-week triple therapy for H pylori eradication
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients with BD
Number of subjects: 45
Study: 16046383

Group type: EXPERIMENTAL
Intervention: ANOVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative approaches
Number of subjects: 0
Study: 12209373

Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation (1.6 mg/day) for 12 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 micro g/day) for 6 weeks followed by folic acid and riboflavin (1.6 mg/day) for 12 weeks
Number of subjects: 52
Study: 10230249

Group type: EXPERIMENTAL
Intervention: ET1 (soft plastic plate with two parallel protrusions)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ET2 (characterised by two lines of 7 holes)
Number of subjects: 96

Group type: COMPARATOR
Intervention: ET1 and ET2
Number of subjects: 96
Study: 8691860

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 25 mg/kg body weight
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 36
Study: 1809790

Group type: EXPERIMENTAL
Intervention: 2% cyclosporine ophthalmic ointment (dosed once, twice, or thrice daily for 14 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 6135720

Group type: EXPERIMENTAL
Intervention: Estazolam 0.25 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Estazolam 0.5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Estazolam 1.0 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Estazolam 2.0 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31256191

Group type: EXPERIMENTAL
Intervention: Active shoulder exercise with a sling suspension system
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bilateral arm training
Number of subjects: 36
Study: 29641366

Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic sphincterotomy (ES)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No prophylactic endoscopic sphincterotomy (control group)
Number of subjects: 54
Study: 27169627

Group type: EXPERIMENTAL
Intervention: SSG and PRP
Number of subjects: 52

Group type: COMPARATOR
Intervention: SSG alone
Number of subjects: 52
Study: 25203806

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 13 to 15 mg/kg/d for 4 weeks
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) and Placebo
Number of subjects: 112
Study: 22748697

Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 20920220

Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention program
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study: 17624979

Group type: EXPERIMENTAL
Intervention: Bupropion + placebo
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Nicotine + placebo
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Bupropion + nicotine
Number of subjects: 588

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 588
Study: 15591756

Group type: EXPERIMENTAL
Intervention: Walking while performing a simple arithmetic task
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Walking while performing a task of verbal fluency
Number of subjects: 30

Group type: COMPARATOR
Intervention: Walking alone
Number of subjects: 30
Study: 12096010

Group type: EXPERIMENTAL
Intervention: Cefepime plus amikacin
Number of subjects: 969

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam plus amikacin
Number of subjects: 969
Study: 10829372

Group type: EXPERIMENTAL
Intervention: Domiciliary care with telephonic fetal heart rate monitoring
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional care with standard midwifery visits
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Domiciliary care
Number of subjects: 81
Study: 8846712

Group type: EXPERIMENTAL
Intervention: ProtoVIEW protocol processing system
Number of subjects: 0
Study: 19256150

Group type: EXPERIMENTAL
Intervention: 40 g vegetable protein diet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Vegetable protein diet plus 3 g/day of oral kanamycin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Single vegetable protein diet
Number of subjects: 5

Group type: COMPARATOR
Intervention: Vegetable protein diet plus kanamycin
Number of subjects: 5
Study: 626697

Group type: EXPERIMENTAL
Intervention: Halothane 0.5%
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Halothane 1%
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study: 31289012

Group type: EXPERIMENTAL
Intervention: Open fetal myelomeningocele repair with incorporation of a skin allograft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prenatal repair (as per MOMS trial)
Number of subjects: 0
Study: 28927961

Group type: EXPERIMENTAL
Intervention: High-frequency (HF; 20 Hz) DTMS
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low-frequency (LF; 1 Hz) DTMS
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham DTMS
Number of subjects: 41
Study: 27643725

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie-Ketogenic (VLCK) diet
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard low-calorie diet
Number of subjects: 89
Study: 23638978

Group type: EXPERIMENTAL
Intervention: 4000 IU of cholecalciferol for 21 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 30
Study: 23760764

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-surgical therapy
Number of subjects: 80
Study: 20438741

Group type: EXPERIMENTAL
Intervention: Modified sham feeding (MSF) with cherry Kool Aid solutions sweetened with aspartame at concentrations of 0, 0.01, 0.03, 0.08 and 0.28%
Number of subjects: 34
Study: 18434268

Group type: EXPERIMENTAL
Intervention: Lornoxicam i.v. 8 mg 20 min before incision (Group PRE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Saline i.v. 20 mins before incision and lornoxicam i.v. 8 mg after skin closure (Group POST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline i.v. 5 min before incision and after skin closure (Group C)
Number of subjects: 60
Study: 16435640

Group type: EXPERIMENTAL
Intervention: Submucosal-administered meperidine (0.5 mg/lb) with oral hydroxyzine (0.5 mg/lb)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral-administered meperidine (1 mg/lb) with oral hydroxyzine (0.5 mg/lb)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Submucosal-administered meperidine (0.5 mg/lb)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral-administered meperidine (1 mg/lb)
Number of subjects: 20
Study: 12805247

Group type: EXPERIMENTAL
Intervention: 500 mg/day vitamin C
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: 50 mg/day vitamin C
Number of subjects: 439

Group type: COMPARATOR
Intervention: Dropout group (no supplementation)
Number of subjects: 439
Study: 10374220

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg daily
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg daily
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8888662

Group type: EXPERIMENTAL
Intervention: sBNP 10 micrograms/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: sBNP 15 micrograms/kg
Number of subjects: 27
Study: 1800394

Group type: EXPERIMENTAL
Intervention: Nifedipine alone (15-60 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nifedipine in combination with dilazep (50 mg three times a day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nifedipine alone and in combination with dilazep
Number of subjects: 33
Study: 6401172

Group type: EXPERIMENTAL
Intervention: NTG spray 0.8 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31804131

Group type: EXPERIMENTAL
Intervention: Fluoroscopically guided interventional interlaminar needling
Number of subjects: 43
Study: 29058942

Group type: EXPERIMENTAL
Intervention: To-do list writing for 5 minutes prior to sleep
Number of subjects: 57

Group type: COMPARATOR
Intervention: Completed activity list writing for 5 minutes prior to sleep
Number of subjects: 57
Study: 27901117

Group type: EXPERIMENTAL
Intervention: High serum uric acid (UA) in men
Number of subjects: 3284

Group type: EXPERIMENTAL
Intervention: High serum uric acid (UA) in women
Number of subjects: 3284
Study: 23949064

Group type: EXPERIMENTAL
Intervention: Pilates (experimental group, n = 18)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Abdominal breathing and active extremity exercises (control group, n = 8)
Number of subjects: 26
Study: 22964150

Group type: EXPERIMENTAL
Intervention: PEG‐IFNa (either PEG‐IFNa‐2a or PEG‐IFNa‐2b) for 48 weeks
Number of subjects: 96
Study: 20351576

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle loading (IML) group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 18177774

Group type: EXPERIMENTAL
Intervention: 1-year behaviour-change programme delivered by trained facilitators in participants' homes
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: 1-year behaviour-change programme delivered by telephone
Number of subjects: 365

Group type: COMPARATOR
Intervention: Brief advice leaflet (control group)
Number of subjects: 365
Study: 15811205

Group type: EXPERIMENTAL
Intervention: 0.5% Timolol LA (TLA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.5% Timolol maleate (TIM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both treatments (TLA and TIM)
Number of subjects: 12
Study: 12861922

Group type: EXPERIMENTAL
Intervention: Collaborative efforts between nurse researchers in the United States and Mexico to decrease the risk of HIV infection.
Number of subjects: 0
Study: 11222785

Group type: EXPERIMENTAL
Intervention: IVIg (1 g/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 9429051

Group type: EXPERIMENTAL
Intervention: Perphenazine 70 micrograms.kg‐1 up to 5 mg
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 260

Group type: COMPARATOR
Intervention: In-hospital vomiting
Number of subjects: 260
Study: 8508192

Group type: EXPERIMENTAL
Intervention: 2.5‐mg boron supplement
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (Boron and Placebo)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Boron supplementation
Number of subjects: 19
Study: 3543767

Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg, four times daily for six weeks, initiated during the third trimester)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (four times daily for six weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg, four times daily for six weeks, initiated during the second trimester)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin (150 mg, four times daily for six weeks)
Number of subjects: 0
Study: 31711153

Group type: EXPERIMENTAL
Intervention: ACEI/ARB treatment
Number of subjects: 3979
Study: 31160218

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg/day
Number of subjects: 7213

Group type: COMPARATOR
Intervention: Aspirin 100 mg/day
Number of subjects: 7213
Study: 29382478

Group type: EXPERIMENTAL
Intervention: Nursing counseling (NC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 100
Study: 25157676

Group type: EXPERIMENTAL
Intervention: SCT-based intervention delivered by newsletters and phone calls over 6 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group receiving information on stress management over 6 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: SCT-based intervention
Number of subjects: 68
Study: 22766391

Group type: EXPERIMENTAL
Intervention: JNJ‐39393406
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 21472661

Group type: EXPERIMENTAL
Intervention: PF-734200 2 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: PF-734200 5 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: PF-734200 10 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: PF-734200 20 mg
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 18784341

Group type: EXPERIMENTAL
Intervention: gD2 DNA vaccine (100 microg, 300 microg, 1,000 microg, or 3,000 microg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: gD2 DNA vaccine (3,000 microg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 62
Study: 17148534

Group type: EXPERIMENTAL
Intervention: Cluster randomisation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Randomised consent
Number of subjects: 53
Study: 14634493

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 microg/kg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10871441

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 326

Group type: COMPARATOR
Intervention: Suction curettage abortion
Number of subjects: 326
Study: 9335405

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 19
Study: 8436250

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Olive oil supplementation
Number of subjects: 23
Study: 30402880

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of M281 (anti-FcRn antibody) at doses of 15 or 30 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: M281 (all doses)
Number of subjects: 50
Study: 29439757

Group type: EXPERIMENTAL
Intervention: 8% Arginine containing toothpaste
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nano-hydroxyapatite toothpaste
Number of subjects: 60
Study: 27704559

Group type: EXPERIMENTAL
Intervention: cTPE (Spectra Optia)
Number of subjects: 27

Group type: COMPARATOR
Intervention: mTPE (Diapact)
Number of subjects: 27
Study: 25103974

Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical nerve stimulation) applied to the stellate ganglion region, 4 times/day for 30 min/session for 5 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham TENS applied to the posterior cervical region (C7‐T4)
Number of subjects: 38
Study: 22289752

Group type: EXPERIMENTAL
Intervention: Anti-neutrophil cytoplasmic antibody (ANCA) in the acute phase of Kawasaki disease
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Anti-neutrophil cytoplasmic antibody (ANCA) in the recovery phase of Kawasaki disease
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Anti-neutrophil cytoplasmic antibody (ANCA) status in Kawasaki disease
Number of subjects: 46
Study: 21362122

Group type: EXPERIMENTAL
Intervention: rGLP-1 (8.5 pmol/kg/min)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: rGLP-1 (5.0 pmol/kg/min)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: rGLP-1 (2.5 pmol/kg/min)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: rGLP-1 (1.25 pmol/kg/min)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 18198650

Group type: EXPERIMENTAL
Intervention: Qiangyue Cream (QYC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Halometasone cream
Number of subjects: 80
Study: 15585690

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (n‐3 PUFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11961504

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 10212709

Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms/kg
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo (Group PP)
Number of subjects: 156
Study: 8800786

Group type: EXPERIMENTAL
Intervention: Visual semiquantitative (SQ) reading
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Quantitative morphometry (QM)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Consensus reading
Number of subjects: 400
Study: 2212452

Group type: EXPERIMENTAL
Intervention: Imidazole salicylate 750 mg three times daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Piroxicam 20 mg once daily
Number of subjects: 38
Study: 417191

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 91

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 91
Study: 29124387

Group type: EXPERIMENTAL
Intervention: Lactobacillus coryniformis K8 CECT5711 (3 × 10^9 CFU/day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 30525347

Group type: EXPERIMENTAL
Intervention: Genetic inhibition of PCSK9
Number of subjects: 5359

Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 5359
Study: 26645417

Group type: EXPERIMENTAL
Intervention: Teacher A's intervention
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Teacher B's intervention
Number of subjects: 2
Study: 24374246

Group type: EXPERIMENTAL
Intervention: Low pneumoperitoneum pressure (LPP; 8 mm Hg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard pneumoperitoneum pressure (SPP; 12 mm Hg)
Number of subjects: 42
Study: 22431961

Group type: EXPERIMENTAL
Intervention: Chronic back pain patients with evidence for root damage
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Chronic back pain patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study: 20637539

Group type: EXPERIMENTAL
Intervention: PCA3 score > or = 35
Number of subjects: 721

Group type: COMPARATOR
Intervention: PSA > or = 3.0 ng/ml
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: PCA3 in men with low PSA
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: PCA3 in men with previous negative biopsy
Number of subjects: 721